US20020168385A1 - Adeno-associated virus vector for boosting immunogenicity of cells - Google Patents
Adeno-associated virus vector for boosting immunogenicity of cells Download PDFInfo
- Publication number
- US20020168385A1 US20020168385A1 US10/188,994 US18899402A US2002168385A1 US 20020168385 A1 US20020168385 A1 US 20020168385A1 US 18899402 A US18899402 A US 18899402A US 2002168385 A1 US2002168385 A1 US 2002168385A1
- Authority
- US
- United States
- Prior art keywords
- cells
- tumor
- immunogenicity
- adeno
- aav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 34
- 230000005847 immunogenicity Effects 0.000 title claims abstract description 23
- 239000013598 vector Substances 0.000 title claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 229960005486 vaccine Drugs 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 67
- 210000004881 tumor cell Anatomy 0.000 claims description 34
- 239000013607 AAV vector Substances 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 description 19
- 201000001441 melanoma Diseases 0.000 description 12
- 238000010361 transduction Methods 0.000 description 12
- 230000026683 transduction Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 9
- 241000700605 Viruses Species 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 101150034762 EBNA3 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 206010027465 Metastases to skin Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710087110 ORF6 protein Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011889 obduction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to an adeno-associated virus vector suited to increase the immunogenicity of cells, a vaccine containing such a vector and the use of both.
- Adeno-associated viruses are single-stranded DNA viruses belonging to the Parvovirus family. AAVs require helper viruses, particularly adenoviruses or herpesviruses, for their replication. In the absence of helper viruses AAVs integrate into the host cell genome, particularly at a specific site on chromosome 19.
- the genome of AAVs is linear and has a length of about 4680 nucleotides. It comprises two reading frames which code for a structural gene and a non-structural gene.
- the structural gene is referred to as cap gene. It is controlled by the P40 promoter and codes for three capsid proteins.
- the non-structural gene is referred to as rep gene and codes for the rep proteins, Rep 78, Rep 68, Rep 52 and Rep 40.
- the two former proteins are expressed under the control of the P5 promoter while the expression of Rep 52 and Rep 40 is controlled by the P19 promoter.
- the functions of the Rep proteins are determined inter alia by the control of replication and transcription of the AAV genome.
- the present invention relates to an adeno-associated virus vector having a foreign DNA which codes for a protein increasing the immunogenicity of cells.
- the present invention is based upon the finding that adeno-associated viruses (AAVS) are suited to transduce tumor cells.
- AAVS adeno-associated viruses
- An Adeno-Associated Virus (AAV) vector according to the invention contains a foreign DNA which codes for a protein boosting the immunogenicity of cells.
- AAV vector refers to any AAV, i.e., virus particle, and the DNA thereof.
- the AAV vector may be present in wild-type or modified form. The latter also means that it comprises expressible E4 sequences, particularly the ORF6 of the E4 sequences, of adenovirus. Moreover, it may be a system of several components that provide individual or all functions of AAV and/or its DNA. Such a system comprises, e.g., a rep-negative AAV vector and means providing an AAV Rep protein.
- the AAV vector may be inserted in cells where it integrates into the genome or remains in episomal form.
- the term “foreign DNA coding for a protein boosting the immunogenicity of cells” encompasses any foreign DNA that may be integrated within an AAV vector and whose expression product can boost the immunogenicity of cells.
- a foreign DNA are genes whose expression products are lacking from or are down-regulated in tumor cells, e.g., MHC-I genes, genes coding for costimulatory molecules, e.g., B7 genes, such as B7.1 and B7.2 genes, genes coding for secretory immunostimulators, e.g., cytokine genes such as IL-2, interferon and GM-CSF genes, and genes that code for tumor-associated antigens, e.g., MAGE1, tyrosinases or viral proteins, e.g., E7 protein of human papilloma virus and EBNA3 protein of Epstein-Barr virus.
- the expression of the foreign DNA be controlled by a heterologous constitutive or inducible promoter such as a tissue-specific or tumor-specific promoter.
- the foreign DNA can be inserted at any position in the AAV vector.
- the foreign DNA is present in or is present in place of the rep gene.
- several foreign DNAs are present in an AAV vector.
- an AAV vector can be prepared as a virus particle as follows: Two plasmids are provided wherein the first plasmid is an AAV plasmid that contains a foreign DNA, e.g. a gene for a B7 molecule, between the 5′- and 3′-ITR sequences of AAV. However, this plasmid referred to as pAAV-B7 does not code for the AAV Rep and AAV Cap proteins. These proteins are encoded by a second plasmid. The second plasmid contains an SV40 origin of replication. The second plasmid is referred to as pSV40oriAAV.
- Both plasmids are transfected into cells expressing an SV40 T antigen.
- Such cells are, e.g., COS cells.
- the SV40 origin of replication of pSV40oriAAV is activated by the T antigen, and the plasmid is replicated.
- a high expression of the AAV Rep and AAV Cap proteins is obtained.
- AAV vectors are obtained as virus particles by infection of the COS cells with a helper virus, e.g., adenovirus.
- the titer is between 10 6 -10 9 virus-particle/ml.
- the immunogenicity of cells can be increased by means of such an AAV vector.
- an AAV vector coding for several proteins boosting the immunogenicity of cells is provided.
- several AAV vectors coding for differing proteins boosting the immunogenicity of cells are provided.
- the increase in immunogenicity can be achieved with cells of any kind, particularly tumor cells or pre-tumor cells such as HPV-transduced cervical cells.
- the cells can be transduced with the AAV vector by conventional methods. If the AAV vector is present as a virus particle, the cells may be infected with the viral particle. However, if the AVV vector is present as DNA, it is advisable to transfect the cells therewith. For example, electroporation and lipofection may be used as transfection techniques.
- the cells can be present in an organism, or the cells to be transduced can also be isolated from an organism, transduced outside the organism and be introduced into the organism again. Such cells are referred to as autologous cells.
- allogenic cells may be used for the transduction. In this connection, it is favorable for the allogenic cells to belong to a HLA type corresponding to the organism.
- the person skilled in the art readily understands methods of providing cells with a certain HLA type.
- the cells particularly tumor cells or pre-tumor cells, to be inactivated before introducing them again into the organism.
- Conventional methods such as irradiation may be used for this purpose.
- Cells that are transduced outside an organism may also be co-cultivated with autologous and/or allogenic nuclear blood cells, particularly lymphocytes, based on the organism.
- the nuclear blood cells may be stimulated by this, and they may be introduced into the organism as such or together with the transduced cells.
- the present invention also relates to a vaccine that comprises an AAV vector according to the invention.
- the vaccine may further comprise conventional auxiliary agents such as buffers, diluents, carriers, etc.
- the AAV vector codes for several proteins boosting the immunogenicity of cells.
- several AAV vectors are provided that code for differing proteins boosting the immunogenicity of cells.
- the vaccine comprises further substances boosting the immunogenicity of cells, particularly tumor-specific antigens. These antigens may be present, e.g., in the form of peptides, particularly synthetic peptides. The antigens may also be present in the form of expression plasmids encoding them that can also code for HLA molecules.
- the vaccine it is especially favorable for the vaccine to also contain the cells transduced by the AAV vector and/or the nuclear blood cells stimulated by these cells. In particular, it is preferred that the cells be inactivated.
- the vaccine contain a replication-defective adenovirus whose E4 sequences are operational. Expressible E4 sequences may also be present on a vector or an E4 protein. It is preferred that the vaccine contain a substance supporting DNA replication. This may be, e.g., hydroxy urea, a topoisomerase inhibitor or a DNA synthesis inhibitor in a minor amount. It may also be favorable to irradiate the vaccine, e.g., X-ray or gamma irradiation.
- the present invention provides methods to transduce cells, particularly tumor cells or pre-tumor cells, more particularly freshly isolated tumor cells, with great efficiency.
- a transduction efficiency of 85 to 95% may be obtained. Therefore, the most differing cells of a tumor may be transduced so that the entire antigen profile of the tumor is detected and clonal selection is prevented.
- transduction of the individual cells may be achieved with a small number of AAV vector molecules such as 10 to 20 molecules per cell. Therefore, the transduction does not cause a cytopathic effect.
- the immune system recognizes the transduced cells and further cells having an equal antigen profile and can eliminate them.
- the present invention is suited to boost the immunogenicity of cells, particularly tumor cells or pre-tumor cells.
- the present invention is adaptable for use in vivo and/or ex vivo gene therapy of serious diseases such as cancers, including malignant melanoma and cervical carcinoma.
- the homogenizate was adjusted with CsCl to a density of 1.4 g/cm 3 and centrifuged at 38,000 rpm for 24 h. Fractions were taken and those having an index of 1.375-1.371 were pooled, centrifuged and dialyzed against Tris buffer. The titer of the AAV virus particles was determined.
- melanoma tissue was isolated from human skin metastases. The melanoma tissue was incubated in a 2% antibiotic solution (antibiotic/antimycotic agent) for 2 ⁇ 30 min. before it was cut into small fragments. The fragments were passed through a metal screen, and the resulting cell suspension was pipetted through a fine screen into a centrifuge tube. Erythrocytes and dead cells were removed via a Ficoll gradient before the living melanoma cells were washed 2 ⁇ with PBS. The melanoma cells were then incorporated into a suitable medium (RPMI 1640, 1% glutamine, 10-20% fetal calf serum, 1% penicillin streptavidin) and placed in tissue culture plates. Prior to the transduction, the melanoma cells were characterized by means of antibodies (S100, HNB-45, company of DA-KO).
- a B7 transduction efficiency of 85-90% was obtained.
- a primary tumor was removed from a tumor patient and treated as described in Example 2. 1 ⁇ 10 6 tumor cells were seeded and infected with a multiplicity of infection of 10 after previous gamma irradiation by 30 Gy with B7.1-AAV and GM-CSF-AAV. Four days after the infection, the expression rate of the foreign genes was determined for B7.1 and GM-CSF by means of Facs-Flow and ELISA, respectively. 20 ml of peripheral blood was withdrawn from the patient. Peripheral blood lymphocytes were isolated by density gradient centrifugation using Ficoll Histopaque.
- 1 ⁇ 10 7 lymphocytes were co-cultivated in RPMI1640 medium, containing 10% heat-inactivated human serum, 2 mM glutamine, non-essential amino acids, 2 mM sodium pyruvate and 100 ⁇ g/ml gentamycin or kanamycin, with the AAV-infected tumor cells to stimulate a tumor-specific immune response by cytotoxic T cells. After one week of co-cultivation, 20 U/ml recombinant human interleukin-2 was added to the medium. At intervals of 10 days, further tumor cells infected with the AAV vectors were added to the culture in a ratio of 1:10 to the lymphocytes. After three weeks of cultivation, the lymphocytes were checked in a cytotoxicity test (chromium release test or europium release test) for their capability of lyzing the tumor cells. 1 ⁇ 10 7 lymphocytes were reinfused intravenously into the patient.
- cytotoxicity test chromium release test or europium release test
Abstract
The present invention provides an Adeno-Associated Virus (AAV) vector having a foreign DNA coding for a protein that boosts immunogenicity of cells. The invention also provides a vaccine containing such a vector and the use of both.
Description
- This application is a continuation of U.S. application Ser. No. 09/685,408, filed Oct. 9, 2000; which is a continuation of U.S. application Ser. No. 09/142,443, filed May 5, 1999, now U.S. Pat. No. 6,171,597; which was the National Stage of International Application No. PCT/DE97/00445, filed Mar. 6, 1997; which claims the benefit of a German Application No. 196 08 751.1, filed Mar. 6, 1996.
- The present invention relates to an adeno-associated virus vector suited to increase the immunogenicity of cells, a vaccine containing such a vector and the use of both.
- It is known that in about 0.5% of cancer patients, e.g., those suffering from malignant melanomas, the tumor reverses completely. In many cancer patients, a control of the tumor also takes place, so that it remains in a stable condition over years. This may be because the immune system influences the course of the cancer.
- Many attempts have been made to activate the immune system, and to detect and eliminate tumor cells. However, these attempts have not yet yielded satisfactory results.
- It is an object of the present invention to provide a product by which the immune system can be stimulated with respect to tumor cells.
- Adeno-associated viruses (AAVs) are single-stranded DNA viruses belonging to the Parvovirus family. AAVs require helper viruses, particularly adenoviruses or herpesviruses, for their replication. In the absence of helper viruses AAVs integrate into the host cell genome, particularly at a specific site on chromosome 19.
- The genome of AAVs is linear and has a length of about 4680 nucleotides. It comprises two reading frames which code for a structural gene and a non-structural gene. The structural gene is referred to as cap gene. It is controlled by the P40 promoter and codes for three capsid proteins. The non-structural gene is referred to as rep gene and codes for the rep proteins, Rep 78, Rep 68, Rep 52 and Rep 40. The two former proteins are expressed under the control of the P5 promoter while the expression of Rep 52 and Rep 40 is controlled by the P19 promoter. The functions of the Rep proteins are determined inter alia by the control of replication and transcription of the AAV genome.
- The present invention relates to an adeno-associated virus vector having a foreign DNA which codes for a protein increasing the immunogenicity of cells.
- The present invention is based upon the finding that adeno-associated viruses (AAVS) are suited to transduce tumor cells.
- An Adeno-Associated Virus (AAV) vector according to the invention contains a foreign DNA which codes for a protein boosting the immunogenicity of cells.
- The term “AAV vector” refers to any AAV, i.e., virus particle, and the DNA thereof. The AAV vector may be present in wild-type or modified form. The latter also means that it comprises expressible E4 sequences, particularly the ORF6 of the E4 sequences, of adenovirus. Moreover, it may be a system of several components that provide individual or all functions of AAV and/or its DNA. Such a system comprises, e.g., a rep-negative AAV vector and means providing an AAV Rep protein. The AAV vector may be inserted in cells where it integrates into the genome or remains in episomal form.
- The term “foreign DNA coding for a protein boosting the immunogenicity of cells” encompasses any foreign DNA that may be integrated within an AAV vector and whose expression product can boost the immunogenicity of cells. Examples of a foreign DNA are genes whose expression products are lacking from or are down-regulated in tumor cells, e.g., MHC-I genes, genes coding for costimulatory molecules, e.g., B7 genes, such as B7.1 and B7.2 genes, genes coding for secretory immunostimulators, e.g., cytokine genes such as IL-2, interferon and GM-CSF genes, and genes that code for tumor-associated antigens, e.g., MAGE1, tyrosinases or viral proteins, e.g., E7 protein of human papilloma virus and EBNA3 protein of Epstein-Barr virus. It is preferred that the expression of the foreign DNA be controlled by a heterologous constitutive or inducible promoter such as a tissue-specific or tumor-specific promoter. Furthermore, the foreign DNA can be inserted at any position in the AAV vector. In this connection, in some embodiments, the foreign DNA is present in or is present in place of the rep gene. In addition, in some embodiments, several foreign DNAs are present in an AAV vector.
- Conventional methods may be used to prepare an AAV vector according to the present invention. For example, an AAV vector can be prepared as a virus particle as follows: Two plasmids are provided wherein the first plasmid is an AAV plasmid that contains a foreign DNA, e.g. a gene for a B7 molecule, between the 5′- and 3′-ITR sequences of AAV. However, this plasmid referred to as pAAV-B7 does not code for the AAV Rep and AAV Cap proteins. These proteins are encoded by a second plasmid. The second plasmid contains an SV40 origin of replication. The second plasmid is referred to as pSV40oriAAV. Both plasmids are transfected into cells expressing an SV40 T antigen. Such cells are, e.g., COS cells. The SV40 origin of replication of pSV40oriAAV is activated by the T antigen, and the plasmid is replicated. A high expression of the AAV Rep and AAV Cap proteins is obtained. AAV vectors are obtained as virus particles by infection of the COS cells with a helper virus, e.g., adenovirus. The titer is between 106-109 virus-particle/ml.
- The immunogenicity of cells can be increased by means of such an AAV vector. In some preferred embodiments, an AAV vector coding for several proteins boosting the immunogenicity of cells is provided. In some other preferred embodiments, several AAV vectors coding for differing proteins boosting the immunogenicity of cells are provided. The increase in immunogenicity can be achieved with cells of any kind, particularly tumor cells or pre-tumor cells such as HPV-transduced cervical cells.
- The cells can be transduced with the AAV vector by conventional methods. If the AAV vector is present as a virus particle, the cells may be infected with the viral particle. However, if the AVV vector is present as DNA, it is advisable to transfect the cells therewith. For example, electroporation and lipofection may be used as transfection techniques. The cells can be present in an organism, or the cells to be transduced can also be isolated from an organism, transduced outside the organism and be introduced into the organism again. Such cells are referred to as autologous cells. Moreover, allogenic cells may be used for the transduction. In this connection, it is favorable for the allogenic cells to belong to a HLA type corresponding to the organism. The person skilled in the art readily understands methods of providing cells with a certain HLA type. In addition, it is preferred for the cells, particularly tumor cells or pre-tumor cells, to be inactivated before introducing them again into the organism. Conventional methods such as irradiation may be used for this purpose.
- Cells that are transduced outside an organism may also be co-cultivated with autologous and/or allogenic nuclear blood cells, particularly lymphocytes, based on the organism. The nuclear blood cells may be stimulated by this, and they may be introduced into the organism as such or together with the transduced cells.
- The present invention also relates to a vaccine that comprises an AAV vector according to the invention. The vaccine may further comprise conventional auxiliary agents such as buffers, diluents, carriers, etc. In some embodiments, the AAV vector codes for several proteins boosting the immunogenicity of cells. In some other embodiments, several AAV vectors are provided that code for differing proteins boosting the immunogenicity of cells. In some preferred embodiments, the vaccine comprises further substances boosting the immunogenicity of cells, particularly tumor-specific antigens. These antigens may be present, e.g., in the form of peptides, particularly synthetic peptides. The antigens may also be present in the form of expression plasmids encoding them that can also code for HLA molecules. It is especially favorable for the vaccine to also contain the cells transduced by the AAV vector and/or the nuclear blood cells stimulated by these cells. In particular, it is preferred that the cells be inactivated. Moreover, it is preferred that the vaccine contain a replication-defective adenovirus whose E4 sequences are operational. Expressible E4 sequences may also be present on a vector or an E4 protein. It is preferred that the vaccine contain a substance supporting DNA replication. This may be, e.g., hydroxy urea, a topoisomerase inhibitor or a DNA synthesis inhibitor in a minor amount. It may also be favorable to irradiate the vaccine, e.g., X-ray or gamma irradiation.
- The present invention provides methods to transduce cells, particularly tumor cells or pre-tumor cells, more particularly freshly isolated tumor cells, with great efficiency. A transduction efficiency of 85 to 95% may be obtained. Therefore, the most differing cells of a tumor may be transduced so that the entire antigen profile of the tumor is detected and clonal selection is prevented. Moreover, transduction of the individual cells may be achieved with a small number of AAV vector molecules such as 10 to 20 molecules per cell. Therefore, the transduction does not cause a cytopathic effect. Hence, the immune system recognizes the transduced cells and further cells having an equal antigen profile and can eliminate them.
- Thus, the present invention is suited to boost the immunogenicity of cells, particularly tumor cells or pre-tumor cells. As a result, the present invention is adaptable for use in vivo and/or ex vivo gene therapy of serious diseases such as cancers, including malignant melanoma and cervical carcinoma.
- The invention is further explained by the following examples. These examples are provided only to further illustrate the present invention.
- Preparation of an AAV Vector.
- 2×108 COS cells were added to 2.5 ml RPMI, in each case with 800 μg of a 1:1 mixture of pSV40oriAAV and pAAV-B7 (cf. description above), and incubated in ice for 10 min. before electroporation was carried out in a total volume of 0.5 ml. Thereafter, the cells were held on ice for 10 min. before they were placed in tissue culture plates. The medium was changed after 24 h and, after another 24 h, the cells were incubated with adenoviruses (10 infectious adenoviruses/COS cell) for 1 h. After another 72 h, the cells were collected and pelleted. The cell pellet was resuspended and homogenized. The homogenizate was adjusted with CsCl to a density of 1.4 g/cm3 and centrifuged at 38,000 rpm for 24 h. Fractions were taken and those having an index of 1.375-1.371 were pooled, centrifuged and dialyzed against Tris buffer. The titer of the AAV virus particles was determined.
- Transduction of Tumor Cells with an AAV Vector.
- Primary melanoma tissue was isolated from human skin metastases. The melanoma tissue was incubated in a 2% antibiotic solution (antibiotic/antimycotic agent) for 2×30 min. before it was cut into small fragments. The fragments were passed through a metal screen, and the resulting cell suspension was pipetted through a fine screen into a centrifuge tube. Erythrocytes and dead cells were removed via a Ficoll gradient before the living melanoma cells were washed 2× with PBS. The melanoma cells were then incorporated into a suitable medium (RPMI 1640, 1% glutamine, 10-20% fetal calf serum, 1% penicillin streptavidin) and placed in tissue culture plates. Prior to the transduction, the melanoma cells were characterized by means of antibodies (S100, HNB-45, company of DA-KO).
- 3×105 melanoma cells were placed in a 24-well tissue culture plate. 3×106 AAV virus particles of Example 1, which code for a B7 molecule, were placed in 250 μl serum-free medium on the melanoma cells. After an incubation period of 1 h, 1.5 ml serum-containing medium were added, and the cells were incubated in an incubator.
- A FACS analysis of the B7 transduction was carried out. Mouse-anti-human B7.2 monoclonal antibodies (Pharmingen) were placed on the cells which were then bound with a FITC-conjugated goat-anti-mouse antibody. Non-specific bonds were ruled out by isotypic controls. A minimum of 10,000 living melanoma cells was used for each analysis. The percentage of positive cells was defined as fraction which are beyond the 99% range of the control group.
- A B7 transduction efficiency of 85-90% was obtained. Parallel experiments in which an AAV virus particle that coded for several proteins boosting the immunogenicity of cells and in which several AAV virus particles that coded for differing proteins boosting the immunogenicity of cells, respectively, was used for the transduction of the tumor cells, showed equal transduction efficiencies for the individual proteins.
- Stimulation of the Immunogencity of Cells by an AAV Vector.
- (a) The stimulation of the immunogenicity of cells was determined by means of inducing a cytotoxic T cell response.
- Melanoma material was removed from various tumor patients. At the same time, blood was taken, and the T cells were accumulated. As described above, the tumor cells were isolated and transduced with the AAV virus particles of Example 1. Thereafter, the T cells were stimulated with the transduced tumor cells. Non-transduced tumor cells were used for the stimulation of the T cells as control.
- The results demonstrated that the activity of the cytotoxic T cells can markedly be increased by stimulation with an AAV virus particle according to the invention.
- In another experiment, a primary tumor was removed from a tumor patient and treated as described in Example 2. 1×106 tumor cells were seeded and infected with a multiplicity of infection of 10 after previous gamma irradiation by 30 Gy with B7.1-AAV and GM-CSF-AAV. Four days after the infection, the expression rate of the foreign genes was determined for B7.1 and GM-CSF by means of Facs-Flow and ELISA, respectively. 20 ml of peripheral blood was withdrawn from the patient. Peripheral blood lymphocytes were isolated by density gradient centrifugation using Ficoll Histopaque. 1×107 lymphocytes were co-cultivated in RPMI1640 medium, containing 10% heat-inactivated human serum, 2 mM glutamine, non-essential amino acids, 2 mM sodium pyruvate and 100 μg/ml gentamycin or kanamycin, with the AAV-infected tumor cells to stimulate a tumor-specific immune response by cytotoxic T cells. After one week of co-cultivation, 20 U/ml recombinant human interleukin-2 was added to the medium. At intervals of 10 days, further tumor cells infected with the AAV vectors were added to the culture in a ratio of 1:10 to the lymphocytes. After three weeks of cultivation, the lymphocytes were checked in a cytotoxicity test (chromium release test or europium release test) for their capability of lyzing the tumor cells. 1×107 lymphocytes were reinfused intravenously into the patient.
- (b) C57/B16 mice were infected with 5,000 living B16-F10 tumor cells each (mouse melanoma model) into the caudal vein. These tumor cells led to the formation of metastases that could be detected after about 20 days by obduction predominantly in the liver and lungs. On days 3, 10 and 17 following the tumor cell injection, part of the mice were immunized with 300,000 B16-F10 tumor cells that had previously been transduced with an AAV virus particle coding for a B7 protein. Thus, the molecule B7 was found on the surface of the tumor cells.
- It showed that the formation of metastases can be inhibited by immunization with an AAV virus particle according to the invention. Parallel experiments in which an AAV virus particle which coded for several proteins boosting the immunogenicity of cells and in which several AAV virus particles that coded for differing proteins boosting the immunogenicity of cells, respectively, was used for the transduction of the tumor cells, showed an even more intense inhibition of the formation of metastases.
- (c) C57/B16 mice were injected subcutaneously in each case 100,000 B16-F10 tumor cells into the back. This resulted in the formation of a tumor that had a circumference of 0.3-0.5 cm after 10 days. At that time, the AAV virus particle of Example 1 (106-108 particles) was injected directly into the tumor.
- The results demonstrate that after the transduction with an AAV virus particle according to the invention, the tumor cells are detected by the immune system and the tumor is eliminated.
Claims (10)
1. A method for treating a tumor patient, said method comprising administering to a tumor patient isolated tumor cells and/or pre-tumor cells that are transduced with an Adeno-Associated Virus vector comprising a foreign DNA coding for a protein that boosts the immunogenicity of a cell.
2. The method according to claim 1 , wherein the foreign DNA comprises a gene selected from the group consisting of a gene whose expression product is lacking or is down-regulated in said tumor cells, a gene coding for a co-stimulatory molecule, a gene coding for a secretory immunostimulator, and a gene coding for a tumor-associated antigen and a viral protein.
3. The method according to claim 1 , wherein the Adeno-Associated Virus vector comprises more than one foreign DNAs.
4. The method according to claim 1 , wherein the foreign DNA is controlled by a heterologous constitutive or inducible promoter.
5. The method according to claim 4 , wherein the promoter is a tissue-specific or tumor-specific promoter.
6. The method according to claim 4 , wherein said Adeno-Associated Virus vector is in the form of a vaccine which contains conventional auxiliary agents.
7. The method according to claim 6 , wherein the vaccine comprises more than one Adeno-Associated Virus vector and each Adeno-Associated Virus vector codes for a different protein that boosts the immunogenicity of a cell.
8. The method according to claim 6 , wherein the vaccine further comprises substances that boost the immunogenicity of a cell.
9. The method according to claim 8 , wherein the substances are tumor-specific antigens.
10. The method according to claim 6 , wherein the AAV vector is present in freshly isolated tumor cells.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/188,994 US20020168385A1 (en) | 1996-03-06 | 2002-07-02 | Adeno-associated virus vector for boosting immunogenicity of cells |
US10/688,120 US7001765B2 (en) | 1996-03-06 | 2003-10-16 | Adeno-associated virus vector for boosting immunogenicity of cells |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19608751A DE19608751B4 (en) | 1996-03-06 | 1996-03-06 | Use of an adeno-associated virus vector to increase the immunogenicity of cells |
DE19608751.1 | 1996-03-06 | ||
US09/142,443 US6171597B1 (en) | 1996-03-06 | 1997-03-06 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
US09/685,408 US6448074B1 (en) | 1996-03-06 | 2000-10-09 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
US10/188,994 US20020168385A1 (en) | 1996-03-06 | 2002-07-02 | Adeno-associated virus vector for boosting immunogenicity of cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/685,408 Continuation US6448074B1 (en) | 1996-03-06 | 2000-10-09 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/688,120 Continuation-In-Part US7001765B2 (en) | 1996-03-06 | 2003-10-16 | Adeno-associated virus vector for boosting immunogenicity of cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020168385A1 true US20020168385A1 (en) | 2002-11-14 |
Family
ID=7787449
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/142,443 Expired - Fee Related US6171597B1 (en) | 1996-03-06 | 1997-03-06 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
US09/685,408 Expired - Fee Related US6448074B1 (en) | 1996-03-06 | 2000-10-09 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
US10/188,994 Abandoned US20020168385A1 (en) | 1996-03-06 | 2002-07-02 | Adeno-associated virus vector for boosting immunogenicity of cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/142,443 Expired - Fee Related US6171597B1 (en) | 1996-03-06 | 1997-03-06 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
US09/685,408 Expired - Fee Related US6448074B1 (en) | 1996-03-06 | 2000-10-09 | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells |
Country Status (5)
Country | Link |
---|---|
US (3) | US6171597B1 (en) |
EP (1) | EP0888457A1 (en) |
JP (1) | JP2000506013A (en) |
DE (1) | DE19608751B4 (en) |
WO (1) | WO1997032988A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU741602B2 (en) | 1998-02-02 | 2001-12-06 | Johns Hopkins University School Of Medicine, The | A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
DE19905501B4 (en) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament |
CA2466530A1 (en) * | 2001-11-09 | 2003-05-15 | Medigene Aktiengesellschaft | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell |
JP2008509168A (en) | 2004-08-13 | 2008-03-27 | マーシャル,バリー,ジェー. | Bacteria delivery system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
JPH08507921A (en) | 1993-03-19 | 1996-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Method for preparing cancer vaccine |
KR960701988A (en) * | 1993-04-20 | 1996-03-28 | 윌리엄 에스. 로빈슨 | METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR IN-FECTIOUS AGENTS |
US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
PT728214E (en) | 1993-11-09 | 2004-11-30 | Ohio Med College | CELL LINES ARE ABLE TO EXPRESS THE ADDITIONAL-ASSOCIATED VIRUS REPLICATION GENE |
FR2712602B1 (en) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Recombinant viruses, preparation and use in gene therapy. |
US5693531A (en) | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
FR2716893B1 (en) * | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Recombinant viruses, their preparation and their therapeutic use. |
WO1995027494A1 (en) | 1994-04-11 | 1995-10-19 | Sloan-Kettering Institute For Cancer Research | DEFECTIVE HERPES AND DEFECTIVE ADENO-ASSOCIATED VIRUS VECTORS WITH p53 FOR THE TREATMENT OF CANCER |
US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
-
1996
- 1996-03-06 DE DE19608751A patent/DE19608751B4/en not_active Expired - Fee Related
-
1997
- 1997-03-06 WO PCT/DE1997/000445 patent/WO1997032988A1/en not_active Application Discontinuation
- 1997-03-06 EP EP97918009A patent/EP0888457A1/en not_active Withdrawn
- 1997-03-06 US US09/142,443 patent/US6171597B1/en not_active Expired - Fee Related
- 1997-03-06 JP JP9531352A patent/JP2000506013A/en not_active Ceased
-
2000
- 2000-10-09 US US09/685,408 patent/US6448074B1/en not_active Expired - Fee Related
-
2002
- 2002-07-02 US US10/188,994 patent/US20020168385A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2000506013A (en) | 2000-05-23 |
EP0888457A1 (en) | 1999-01-07 |
WO1997032988A1 (en) | 1997-09-12 |
DE19608751A1 (en) | 1997-09-11 |
US6448074B1 (en) | 2002-09-10 |
US6171597B1 (en) | 2001-01-09 |
DE19608751B4 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7001765B2 (en) | Adeno-associated virus vector for boosting immunogenicity of cells | |
US6210963B1 (en) | Recombinant cells from the monocyte-macrophage cell line for gene therapy | |
Yamashita et al. | Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model | |
KR100421753B1 (en) | Adeno-associated viral(AAV) liposomes and methods related thereto | |
Sarukhan et al. | Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors | |
JP4094053B2 (en) | Anti-cancer gene therapy by modulating immune or inflammatory response | |
CN102268453A (en) | LMP-1 recombinant adeno-associated virus (rAAV) vector and construction method as well as application thereof | |
EP0840622A1 (en) | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity | |
JP7420751B2 (en) | Oncolytic virus- or antigen-presenting cell-mediated cancer therapy using type I interferon and CD40-ligand | |
Terando et al. | Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector | |
WO2020259151A1 (en) | Preparation method and application of ctl cell | |
US6448074B1 (en) | Adeno-associated virus vector for boosting immunogenicity of freshly isolated tumor cells | |
Lu et al. | Modulating oncolytic adenovirus immunotherapy by driving two axes of the immune system by expressing 4-1bbl and cd40l | |
Roddie et al. | Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines | |
CN105087648A (en) | Recombinant adeno-associated virus vector carrying MAGE-A3 gene as well as construction method and application | |
CA2655990A1 (en) | Restoration of hearing loss | |
Philip et al. | Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. | |
Kerr et al. | Gene therapy: current status and future prospects | |
CN116478932A (en) | Genetically modified immune cells and uses thereof | |
Howard et al. | Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer | |
Wahl et al. | Generation of therapeutic T-lymphocytes after in vivo tumor transfection with an allogeneic class I major histocompatibility complex gene | |
Veron et al. | Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation | |
US7064111B1 (en) | Use of soluble costimulatory factor for tumor immuno-gene therapy | |
EP0825873B1 (en) | Anticancer vaccine comprising il6/il6 receptor transfected cells | |
CN105087649A (en) | MUC-1 antigen gene carried recombinant adeno-associated virus vector as well as construction method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |